Vaccine one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was first noted in the trivalent Sabin polio vaccine, where the amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype 1 and 3 viruses in the vaccine. This phenomenon has also been found to be a problem with the dengue vaccines currently being researched, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, −2 and −4 serotypes.
Sabin Vaccine Institute Development, the Global Network for Neglected Tropical Diseases, and Vaccine Advocacy and Education. Through its Product Development Partnership (PDP), Sabin has worked with organizations such as King Saud University, Texas Children's Hospital Center, International Vaccine Institute, and George Washington University School of Medicine & Health Sciences toward its goals, with funding and support from the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases, the Dutch Ministry of Foreign Affairs, the Brazilian Ministry of Health and other benefactors. In 2012, Sabin partnered with International Vaccine Institute to combine their research, development, and promotion efforts in Asia,